Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | FCER2 | P06734 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | TPH1 | P17752 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27508894 | 0.72 | CASR (0.51) | KIF11PTPN1CASRCYP3A4CYP2D6 | |
| SCHEMBL8582070 | 0.72 | SLC6A2 (0.39) | EPHX1KIF11PTPN1CASRCYP3A4 | |
| SCHEMBL548731 | 0.72 | PTPN1 (0.50) | PTPN1CASRCYP3A4CYP2D6SLC6A2 | |
| SCHEMBL7132144 | 0.72 | CASR (0.58) | PTPN1CASRCYP3A4CYP2D6SLC6A2 | |
| SCHEMBL29226433 | 0.71 | PTPN1 (0.47) | KIF11PTPN1CASRCYP3A4CYP2D6 | |
| SCHEMBL7861321 | 0.71 | PTPN1 (0.47) | KIF11PTPN1CASRCYP3A4CYP2D6 | |
| SCHEMBL29941124 | 0.71 | PTPN1 (0.47) | KIF11PTPN1CASRCYP3A4CYP2D6 | |
| SCHEMBL514964 | 0.70 | CYP1A2 (0.51) | EPHX1KIF11PTPN1CASRCYP3A4 | |
| SCHEMBL4755686 | 0.70 | CYP1A2 (0.51) | EPHX1KIF11PTPN1CASRCYP3A4 | |
| SCHEMBL27941075 | 0.70 | MAPT (0.58) | EPHX1KIF11PTPN1CASRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050058725-A1 | Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent | MCKEARN JOHN P (US) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050058725-A1 | Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent | MMP3, MMP10, MMP25 | EPHX1 1107/4885KIF11 3440/4885PTPN1 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.